Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

MLA

Ashraf Badros, et al. “Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma.” Journal of Clinical Oncology, vol. 28, June 2010, pp. 3015–22. EBSCOhost, https://doi.org/10.1200/jco.2009.26.1347.

APA

Ashraf Badros, R. Donald Harvey, Rong Chen, Tianling Chen, Kristi Mahadocon, Judith A. Fox, Rajni Sinha, David A. Siegel, Wei Gang Tong, William G. Wierda, Peggy Kegley, William Plunkett, Ute Hoch, Steven Coutre, & Leslie Popplewell. (2010). Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma. Journal of Clinical Oncology, 28, 3015–3022. https://doi.org/10.1200/jco.2009.26.1347

Chicago

Ashraf Badros, R. Donald Harvey, Rong Chen, Tianling Chen, Kristi Mahadocon, Judith A. Fox, Rajni Sinha, et al. 2010. “Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma.” Journal of Clinical Oncology 28 (June): 3015–22. doi:10.1200/jco.2009.26.1347.